• RG7388: Applied MDM2 Antagonist Workflows

  2026-08-17

  RG7388 connects biochemical disruption of the p53-MDM2 interaction with practical cell-based apoptosis and combination-treatment workflows. This guide shows how to select responsive models, control compound handling, interpret p53 pathway activation, and use the MDM1-p53 findings from colorectal cancer research without overextending the evidence.

• AICAR: AMPK Activation for Metabolic Research

  2026-08-16

  AICAR is a cell-permeable pharmacological tool for studying AMPK-dependent energy metabolism regulation, inflammatory signaling, and cellular stress protection. Its intracellular AMP-mimetic activity supports metabolic research, but concentration, cell type, and pathway-specific controls are essential for interpretation.

• (S)-Mephenytoin in CYP2C19 Organoid Assays

  2026-08-15

  (S)-Mephenytoin provides a practical CYP2C19 substrate for connecting human intestinal organoid biology with oxidative drug metabolism. This workflow combines parent-drug depletion, 4-hydroxy metabolite formation, barrier assessment, and controls that help distinguish enzyme activity from permeability or culture artifacts.

• 8-Chloroadenosine in Translational RNA Research

  2026-08-15

  8-Chloroadenosine provides translational researchers with a chemical lens for connecting RNA synthesis, lncRNA-mediated mRNA stability, and tumor-cell phenotypes. This article shows how to position the nucleoside analog alongside genetic perturbation and RNA-decay assays to strengthen mechanistic validation in NSCLC and broader RNA metabolism studies.

• Light-Inducible RNA Release for Gene Therapy

  2026-08-14

  The reference study presents a rationally designed light-inducible RNA-releasing protein, or LIRP, that controls therapeutic protein production at the translation stage rather than through conventional transcriptional switches. In mouse models, the system enabled reversible, light-dependent regulation of transgenes in skin and retina, illustrating how ambient light or darkness could provide an external control layer for chronic and retinal gene therapies.

• Bobcat339 for TET-Linked DNA Methylation Studies

  2026-08-14

  Bobcat339 is a cytosine structure-based TET enzyme inhibitor for separating TET-dependent DNA demethylation from UHRF1-associated 5-mC and enhancer effects. This practical workflow combines dose-response testing with methylation, enhancer, transcriptional, and osteogenic readouts to support mechanism-focused epigenetics research.

• PF-573228: FAK Inhibitor Workflow for Mechanobiology

  2026-08-13

  PF-573228 connects focal-adhesion signaling with substrate mechanics, cancer-cell behavior, and endothelial phenotypes in one experimentally tractable workflow. Use it as a timed pathway perturbation tool to distinguish stiffness-driven differentiation from downstream effects on migration, survival, and angiogenesis.

• Amyloid Beta-peptide (25-35): Assay Logic

  2026-08-13

  Amyloid Beta-peptide (25-35) is a powerful acute model for separating neuronal injury from inflammatory signaling in Alzheimer’s disease research. This guide connects peptide handling and endpoint selection with the FLOT1–FOSL2–EphA2 findings to improve mechanistic assay design.

• Nintedanib (BIBF 1120): Mechanism and Research Use

  2026-08-12

  Nintedanib, also called BIBF 1120, is an orally active triple angiokinase inhibitor of VEGFR, FGFR, and PDGFR signaling. Its nanomolar kinase-inhibition profile supports antiangiogenic, antifibrotic, and oncology research, while ATRX-deficient glioma findings provide a genotype-aware rationale for studying receptor tyrosine kinase inhibitors.

• Shufeng Xingbi Therapy in Allergic Rhinitis Rats

  2026-08-12

  This preprint evaluates Shufeng Xingbi Therapy in an ovalbumin-induced rat model of allergic rhinitis using behavioral, histological, immunological, gene-expression, and gut-microbiome measurements. The findings link symptom improvement with reduced IgE/IL-4-associated inflammation, altered Th1/Th2-related signaling, increased serum short-chain fatty acids, and shifts in fecal bacterial composition, while also highlighting important limits on causal and clinical interpretation.

• Phosbind Biotin for Phosphorylation Analysis

  2026-08-11

  Phosbind Biotin enables sequence-independent Western Blot detection of phosphorylated proteins when a suitable phospho-specific antibody is unavailable or too narrow. This practical guide connects dinuclear metal complex phosphate binding with drought-response research, experimental design, workflow optimization, and troubleshooting.

• Vacuolin-1: From Fusion Blockade to Translation

  2026-08-10

  Lysosomal exocytosis is emerging as an active driver of tissue pathology rather than a passive consequence of storage. This thought-leadership guide explains how Vacuolin-1 can help translational researchers test the causal role of lysosome–plasma membrane fusion in membrane repair, calcium signaling, lysosomal β-hexosaminidase release, and MPS IVA disease models.

• Praeruptorin A Workflows for Inflammation Research

  2026-08-09

  Build mechanism-led assays around Praeruptorin A, an angular pyranocoumarin compound for studying inflammation, ferroptosis, intestinal barrier repair, cardiac injury, and tumor-cell invasion. Practical dose planning, controls, and troubleshooting help distinguish pathway modulation from solvent effects or nonspecific cytotoxicity.

• Acquired CDK7 Inhibitor Resistance in Cancer

  2026-08-08

  The reference study identifies a CDK7 Asp97Asn mutation that emerges during Samuraciclib selection and selectively reduces sensitivity to non-covalent CDK7 inhibitors. Structural, biochemical, and genetic analyses show that this conserved-residue mechanism may also shape resistance to CDK12 and CDK4 inhibitors, while covalent CDK7 inhibitors retain activity against the CDK7-D97N mutant.

• 3D Spheroid Assay for Glioblastoma Stemness

  2026-08-07

  This 2026 Stem Cell Research protocol presents a streamlined 96-well 3D-tumor spheroid assay for functionally assessing stem-like behavior in human glioma cell lines. Its reduced handling burden and shorter workflow may support reproducible stemness comparisons and exploratory therapeutic screening, while spheroid formation remains a surrogate phenotype that requires orthogonal validation.

456 records 8/31 page Previous Next First page 上5页 678910 下5页 Last page